CA
ADMS

Cliff Asness’s Adamas Pharmaceuticals ADMS Stock Holding History

Cliff Asness’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-420,304
Closed -$1.08M – 2307
2020
Q2 		$1.08M Buy
420,304
+203,582
+94% +$598K ﹤0.01% 1435
2020
Q1 		$626K Buy
216,722
+169,014
+354% +$757K ﹤0.01% 1508
2019
Q4 		$181K Buy
+47,708
New +$228K ﹤0.01% 2022
2018
Q4 		– Sell
-14,897
Closed -$298K – 2317
2018
Q3 		$298K Sell
14,897
-917
-6% -$21.5K ﹤0.01% 2110
2018
Q2 		$408K Buy
15,814
+3,310
+26% +$91.7K ﹤0.01% 2046
2018
Q1 		$299K Buy
12,504
+3,329
+36% +$105K ﹤0.01% 2048
2017
Q4 		$311K Buy
+9,175
New +$256K ﹤0.01% 2059
2016
Q1 		– Sell
-9,964
Closed -$282K – 2311
2015
Q4 		$282K Buy
+9,964
New +$168K ﹤0.01% 2054

Other funds holding ADMS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Cliff Asness's ADMS Position: Q3 2020 in Review

Cliff Asness sold out of Adamas Pharmaceuticals (ADMS) in Q3 2020, closing a stake of 420,304 shares — an estimated $1.08M sold.

Cliff Asness first reported a position in ADMS in Q4 2015 and held it in 8 quarters. The position peaked at $1.08M in Q2 2020. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2020.

  • Cliff Asness reported no remaining Adamas Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Cliff Asness sold 420,304 Adamas Pharmaceuticals shares in Q3 2020, an estimated $1.08M.
  • Cliff Asness first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Cliff Asness's Adamas Pharmaceuticals position peaked at $1.08M in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2020.

Based on AQR Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.